Tumor microvasculature as a barrier to antitumor immunity.
作者信息
Chen Qing, Wang Wan-Chao, Evans Sharon S
机构信息
Department of Immunology, Roswell Park Cancer Institute, Carlton and Elm Streets, NY 14263, Buffalo, USA.
出版信息
Cancer Immunol Immunother. 2003 Nov;52(11):670-9. doi: 10.1007/s00262-003-0425-4. Epub 2003 Aug 15.
Abstract
摘要
相似文献
1
Tumor microvasculature as a barrier to antitumor immunity.肿瘤微血管作为抗肿瘤免疫的屏障。
Cancer Immunol Immunother. 2003 Nov;52(11):670-9. doi: 10.1007/s00262-003-0425-4. Epub 2003 Aug 15.
2
Vascular Microenvironment, Tumor Immunity and Immunotherapy.血管微环境、肿瘤免疫与免疫治疗。
Front Immunol. 2021 Dec 20;12:811485. doi: 10.3389/fimmu.2021.811485. eCollection 2021.
3
T-cell interactions with extracellular matrix proteins and endothelium in chronic renal allograft rejection.慢性肾移植排斥反应中T细胞与细胞外基质蛋白及内皮的相互作用
Transplant Proc. 1997 Feb-Mar;29(1-2):1057-9. doi: 10.1016/s0041-1345(96)00379-x.
4
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?肿瘤浸润淋巴细胞在实体瘤患者中的作用：水滴石穿？
Cell Immunol. 2019 Sep;343:103753. doi: 10.1016/j.cellimm.2018.01.013. Epub 2018 Feb 1.
5
Tumor-infiltrating lymphocytes as antitumor effector cells.肿瘤浸润淋巴细胞作为抗肿瘤效应细胞。
Biotherapy. 1992;5(1):47-61. doi: 10.1007/BF02194785.
6
Tumor blood vessels, a difficult hurdle for infiltrating leukocytes.肿瘤血管是浸润白细胞的一个难题。
Biochim Biophys Acta. 2007 Dec;1776(2):160-74. doi: 10.1016/j.bbcan.2007.07.005. Epub 2007 Aug 15.
7
Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium.血管黏附蛋白1介导免疫治疗效应细胞与肿瘤内皮的结合。
J Immunol. 2001 Jun 1;166(11):6937-43. doi: 10.4049/jimmunol.166.11.6937.
8
Tissue-resident memory T cells in tumor immunity and immunotherapy.肿瘤免疫与免疫治疗中的组织驻留记忆 T 细胞。
J Exp Med. 2021 Apr 5;218(4). doi: 10.1084/jem.20201605.
9
Manipulating the microbiome to improve the efficacy of immunotherapy.操纵微生物群以提高免疫疗法的疗效。
Clin Adv Hematol Oncol. 2016 Jun;14(6):424-6.
10
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.肿瘤浸润免疫细胞与预后：常规癌症疗法与免疫之间的潜在联系。
Exp Biol Med (Maywood). 2011 May 1;236(5):567-79. doi: 10.1258/ebm.2011.011007. Epub 2011 Apr 12.
引用本文的文献
1
The 11th International Conference on cGMP 2024: recent trends and developments in cGMP research -meeting report.2024年第11届国际cGMP会议：cGMP研究的最新趋势与进展——会议报告
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 7. doi: 10.1007/s00210-025-04059-1.
2
Interrelationships between the extracellular matrix and the immune microenvironment that govern epithelial tumour progression.调控上皮性肿瘤进展的细胞外基质与免疫微环境之间的相互关系。
Clin Sci (Lond). 2022 Mar 18;136(5):361-377. doi: 10.1042/CS20210679.
3
Leveraging microenvironmental synthetic lethalities to treat cancer.利用微环境合成致死性治疗癌症。
J Clin Invest. 2021 Mar 15;131(6). doi: 10.1172/JCI143765.
4
Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored.辐射唤醒休眠免疫系统，一项有待探索的充满希望的挑战。
Front Immunol. 2014 Mar 14;5:102. doi: 10.3389/fimmu.2014.00102. eCollection 2014.
5
Characteristics of tertiary lymphoid structures in primary cancers.原发性癌症中的三级淋巴结构特征。
Oncoimmunology. 2013 Dec 1;2(12):e26836. doi: 10.4161/onci.26836. Epub 2013 Oct 22.
6
Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity.预处理性热疗：开启 IL-6 开关以获得抗肿瘤免疫。
Int J Hyperthermia. 2013 Aug;29(5):464-73. doi: 10.3109/02656736.2013.807440. Epub 2013 Jul 17.
7
High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.人类黑色素瘤病变中的高内皮小静脉 (HEVs)：肿瘤浸润淋巴细胞的主要门户。
Oncoimmunology. 2012 Sep 1;1(6):829-839. doi: 10.4161/onci.20492.
8
Role of T lymphocytes in tumor response to radiotherapy.T 淋巴细胞在肿瘤放疗反应中的作用。
Front Oncol. 2012 Aug 24;2:95. doi: 10.3389/fonc.2012.00095. eCollection 2012.
9
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.基质架构定义了 T 细胞优先定位于并迁移至人肺部肿瘤基质的特征。
J Clin Invest. 2012 Mar;122(3):899-910. doi: 10.1172/JCI45817. Epub 2012 Feb 1.
10
Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.硫代二半乳糖苷通过同时阻断半乳糖凝集素-1对免疫失调、血管生成和抗氧化应激的作用来抑制小鼠癌症。
Angiogenesis. 2011 Sep;14(3):293-307. doi: 10.1007/s10456-011-9213-5. Epub 2011 Apr 27.
本文引用的文献
1
Role of cytokines in photodynamic therapy-induced local and systemic inflammation.细胞因子在光动力疗法诱导的局部和全身炎症中的作用。
Br J Cancer. 2003 Jun 2;88(11):1772-9. doi: 10.1038/sj.bjc.6600864.
2
SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.SLC/CCL21介导的抗肿瘤反应需要IFNγ、MIG/CXCL9和IP-10/CXCL10。
Mol Cancer. 2003 Apr 15;2:22. doi: 10.1186/1476-4598-2-22.
3
Chemokines as therapeutic targets in non-small cell lung cancer.趋化因子作为非小细胞肺癌的治疗靶点
Curr Med Chem Anticancer Agents. 2002 May;2(3):403-17. doi: 10.2174/1568011024606406.
4
Cytokine and adhesion molecule expression in primary human endothelial cells stimulated with fever-range hyperthermia.发热范围高温刺激下人原代内皮细胞中细胞因子和黏附分子的表达
Int J Hyperthermia. 2002 Nov-Dec;18(6):534-51. doi: 10.1080/02656730210157843.
5
Rational approaches to human cancer immunotherapy.人类癌症免疫治疗的合理方法。
J Leukoc Biol. 2003 Jan;73(1):3-29. doi: 10.1189/jlb.0502261.
6
Cytokine modified tumor vaccines.细胞因子修饰的肿瘤疫苗
Surg Oncol Clin N Am. 2002 Jul;11(3):681-96. doi: 10.1016/s1055-3207(02)00020-0.
7
Adjuvant immunotherapy for solid tumors: from promise to clinical application.实体瘤的辅助免疫治疗：从前景到临床应用
Cancer Immunol Immunother. 2002 Dec;51(11-12):583-95. doi: 10.1007/s00262-002-0308-0. Epub 2002 Sep 17.
8
Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.法莫替丁是否能增强乳腺癌中的肿瘤浸润淋巴细胞？一项随机前瞻性初步研究的结果。
Acta Oncol. 2002;41(4):362-5. doi: 10.1080/028418602760169415.
9
Hyperthermia in combined treatment of cancer.热疗在癌症联合治疗中的应用
Lancet Oncol. 2002 Aug;3(8):487-97. doi: 10.1016/s1470-2045(02)00818-5.
10
Endothelial activation: intracellular signaling pathways.内皮细胞活化：细胞内信号通路
Arthritis Res. 2002;4 Suppl 3(Suppl 3):S109-16. doi: 10.1186/ar576. Epub 2002 May 9.
Zotero 插件